DEVELOPMENT OF PATIENT-REPORTED OUTCOME (PRO) AND OBSERVER-REPORTED OUTCOME (OBSRO) MEASURES FOR ASSESSMENT OF SYMPTOM INTENSITY IN DENGUE ILLNESS

Author(s)

Saretsky T1, Marks M2, Sinha A2, Cuesta H2, Coller BA2, Lee AWT2, Wells JR3, Gater A3, Morrison AC4, Paz-Soldan VA5, Endy T6, Thomas S7, Panter C3
1Merck & Co., Inc., North Wales, PA, USA, 2Merck & Co., Inc., Kenilworth, NJ, USA, 3Patient-Centered Outcomes, Adelphi Values Ltd., Bollington, UK, 4Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, CA, USA, 5International Health and Development Department, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA, 6Infectious Disease Division, Department of Medicine, State University of New York Upstate Medical University, Syracuse, NY, USA, 7Division of Infectious Diseases, State University of New York, Upstate Medical University, Syracuse, NY, USA

OBJECTIVES: Signs and symptoms of dengue disease are typically evaluated by clinicians in research studies at time of febrile illness onset and resolution. Outcomes based on the dengue patient experience, especially in the outpatient setting, have received less attention, limiting understanding of dengue illness burden. The aim of this study is to use patient input to develop the Dengue Illness Daily Diary (DIDD), a new Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) measure for use in children, adolescents and adults in outpatient settings. The DIDD was adapted from an existing PRO measure, the Dengue Illness Index Report Card (DII-RC), developed with clinician input only. METHODS: Face validity assessment was conducted in accordance with FDA PRO Guidance, ISPOR PRO good research practices, and the dengue literature. Recommended modifications were discussed with dengue scientific and clinical experts to achieve consensus. A preliminary translatability assessment was conducted to confirm appropriateness for use in dengue endemic countries. Patient interviews will be conducted in Peru. RESULTS: Concepts captured in the DIDD include fever, tiredness, rash, itchy skin, appetite loss, nausea, vomiting, diarrhea, headache, pain, eye redness, bruising, sleep, mood, daily functioning, and overall health. Response options capture gradation in sign and symptom intensity. Item and instruction wording, and general instrument format were aligned with outcomes from the face validity assessment and translatability assessment. The DIDD was migrated to electronic format. CONCLUSIONS: The DIDD aims to characterize the dengue illness burden from the patient’s perspective. Concepts, response options, item and instruction wording, and general format, were modified from an existing instrument and are consistent with PRO published standards, the dengue literature, and expert opinion. Qualitative interviews with dengue patients and caregivers are planned in Peru to establish content validity and test for usability and feasibility of the instrument in paper and electronic format.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PIN96

Topic

Clinical Outcomes, Methodological & Statistical Research, Patient-Centered Research

Topic Subcategory

Clinical Outcomes Assessment, Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes, PRO & Related Methods

Disease

Infectious Disease (non-vaccine)

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×